Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Clin Exp Pharmacol Physiol. 2012 May;39(5):454–461. doi: 10.1111/j.1440-1681.2012.05699.x

Fig. 1.

Fig. 1

Systolic blood pressure in control (vehicle-treated; △), sorafenib-treated (□) and sorafenib + captopril-treated (○) rats. Rats were treated over a period of 4 weeks. Systolic blood pressure was measured by tail-cuff plethysmography. Data are the mean ± SEM (n = 6 in each group). *P < 0.05 compared with vehicle control; P < 0.05 compared with the sorafenib-treated group (one-way ANOVA followed by Tukey’s post hoc test).